Down’s syndrome (DS) is one of the oldest known human malformation syndromes; paintings dating back to the sixteenth century have been found that suggest depictions of individuals with phenotypic features of DS. The pattern of malformation was formally recognized during a lecture given in 1846 by Edouard Seguin. The syndrome’s namesake, Dr. John Langdon Down, described this congenital syndrome characterized by stereotypic facial and cognitive features for the first time in the medical literature in 1866 (1, 2). Although advanced maternal age was understood to be a risk factor for DS, trisomy 21 as the cause of DS was not appreciated until 1959 when Lejeune confirmed the presence of three copies of human chromosome 21 in nine infants with DS (3). In 1948, Jervis reported finding neuropathologic features of Alzheimer’s disease [AD, originally described by Alzheimer in 1907 (4)] in three adults with DS at 35, 42, and 47 years of age (5). DS is one of the most common human genetic disorders with a prevalence of approximately 1 in 700 births (including live and still births) (6).